Skip to main content
. 2022 Jan 1;15(1):38–48. doi: 10.1007/s12265-021-10147-3

Fig. 1.

Fig. 1

Laboratory test results in hypertensive COVID-19 patients with or without AT1R blocker treatment (a) and surviving or non-surviving hypertensive COVID-19 patients (b). Continuous variables with normal distribution were expressed as mean (SD) and compared using Student’s t-test; categorical variables were expressed as number (%) and compared using χ2 test or Fisher’s exact test. AT1RB = patients on AT1R blockers; Non-AT1RB = patents on antihypertensive treatment other than AT1R blockers. *P<0.01 vs. AT1RB group; ***P<0.0001 vs. survivor group